August 20, Blueprint Medicines is working with The Life Raft Group and GIST Support International to host a webinar providing a data update from the registration-enabling NAVIGATOR trial of the investigational treatment avapritinib in patients with PDGFRA Exon 18 mutant GIST and fourth-line GIST.
Case Presentations October 26, 12PM ET Please join us for the second webcast of our Women in Sarcoma series. The Life Raft Group has developed the Women in Sarcoma program in recognition of the [...]
As the landscape of GIST treatment continues to evolve, the area of immunotherapy has grown interest. GIST contains tumor-infiltrating immune cells which opens the possibility to the rationale for immunotherapy treatments. This webinar will [...]